35 min listen
The Latest Breakthroughs in Immunotherapy for GU Cancers
FromAUAUniversity
ratings:
Length:
37 minutes
Released:
Dec 27, 2023
Format:
Podcast episode
Description
The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:
The Latest Breakthroughs in Immunotherapy for GU Cancers
CME Available: https://auau.auanet.org/node/39543
Release Date: December, 2023
Expiration Date: December, 2024
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Identify the newest immunotherapy drugs approved for prostate, bladder, and kidney cancer, including immune checkpoint inhibitors and other novel immunotherapies.
2. Discuss the clinical evidence supporting the use of these immunotherapy drugs in prostate, bladder, and kidney cancer, including data from pivotal clinical trials, response rates, and survival outcomes.
3. Evaluate the safety profile and potential immune-related adverse events associated with the newest immunotherapy drugs in GU cancers.
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.
The Latest Breakthroughs in Immunotherapy for GU Cancers
CME Available: https://auau.auanet.org/node/39543
Release Date: December, 2023
Expiration Date: December, 2024
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Identify the newest immunotherapy drugs approved for prostate, bladder, and kidney cancer, including immune checkpoint inhibitors and other novel immunotherapies.
2. Discuss the clinical evidence supporting the use of these immunotherapy drugs in prostate, bladder, and kidney cancer, including data from pivotal clinical trials, response rates, and survival outcomes.
3. Evaluate the safety profile and potential immune-related adverse events associated with the newest immunotherapy drugs in GU cancers.
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.
Released:
Dec 27, 2023
Format:
Podcast episode
Titles in the series (40)
How Can We Improve SDM A Prostate Cancer Survivor’s Perspective: Support provided by independent educational grant… by AUAUniversity